Clonidine Hydrochloride Tablets, USP 0.1mg, Rx Only, 100-count bottle, Manufactured by: Unichem L...
FDA Drug Recall #D-0829-2020 — Class III — January 29, 2020
Recall Summary
| Recall Number | D-0829-2020 |
| Classification | Class III — Low risk |
| Date Initiated | January 29, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | UNICHEM PHARMACEUTICALS USA INC |
| Location | East Brunswick, NJ |
| Product Type | Drugs |
| Quantity | 19161600 units |
Product Description
Clonidine Hydrochloride Tablets, USP 0.1mg, Rx Only, 100-count bottle, Manufactured by: Unichem Laboratories Ltd. Pilerne Ind. Estate, Pilerne Bardez, Goa 403 511 India. Manufactured for: Unichem Pharmaceuticals (USA), Inc. East Brunswick, NJ 08816. NDC 29300-135-01
Reason for Recall
Failed Impurities/Degredation Specifications: This recall is initiated as a precautionary measure due to potential migration of Benzophenone at very low level into product from container label.
Distribution Pattern
Distributed Nationwide in the US
Lot / Code Information
Lot Numbers: GCLL18108, GCLL18109, GCLL18110 - EXP 10/31/2020; GCLL19003 EXP 12/31/2020
Other Recalls from UNICHEM PHARMACEUTICALS USA INC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1541-2022 | Class III | Clonidine Hydrochloride Tablets, USP, 0.3 mg, 1... | Sep 19, 2022 |
| D-0255-2022 | Class III | Topiramate Tablets, USP 50 mg, 500-count bottle... | Oct 25, 2021 |
| D-1291-2020 | Class III | Clonidine Hydrochloride Tablets, USP 0.1 mg 100... | May 26, 2020 |
| D-0228-2018 | Class II | Divalproex Sodium Delayed Release Tablets USP, ... | Dec 19, 2017 |
| D-0010-2018 | Class II | Bisoprolol Fumarate tablets, 5 mg, 30-count b... | Oct 2, 2017 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.